Retrospective 1,395 vaccinated COVID-19 cases, showing significantly lower hospitalization and oxygen supplementation with monoclonal antibody treatment, primarily casirivimab-imdevimab. Hospitalization was significantly associated with comorbidities.


risk of ICU admission, 88.9% lower, RR 0.11, p = 0.16
, treatment 0 of 527 (0.0%), control 5 of 868 (0.6%), NNT 174, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).


risk of oxygen therapy, 85.3% lower, RR 0.15, p , treatment 5 of 527 (0.9%), control 56 of 868 (6.5%), NNT 18, odds ratio converted to relative risk.


risk of hospitalization, 75.3% lower, RR 0.25, p , treatment 14 of 527 (2.7%), control 93 of 868 (10.7%), NNT 12, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes.

This study is excluded:

patients were treated with different medications, results specific to each medication were not reported.

Conflicts of interest:
research funding from the drug patent holder.

Bierle et al., 10/20/2021, retrospective, USA, North America, peer-reviewed, 7 authors.

Contact:
[email protected].

Source link